Cystic Fibrosis Australia CEO Nettie Burke is currently attending the European Conference and has just seen the Orkambi 96 week trial results.

"Most importantly, matched cohort analysis demonstrated that Orkambi reduced the annual rate of lung function decline by 40%, an effect similar to the 47% reduction observed in Kalydeco. Exaserbations and hospitalisations remained low and BMI continued to improve."

Read more>